We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Disappointing stocks are everywhere. I’m sorry if I am the one who had to tell you but it’s true. With the market chopping around, worried about Pelosi vs Mnuchin, you know what I mean. We need a deal done now. Actually, it should have happened six months ago…but I digress.
This brings to mind something I like to call the Bear of the Day. Now, before you folks get upset with me for calling out what is inevitably your favorite stock, bear with me for a moment (see what I did there.)
The Bear of the Day to me, is not necessarily, a stock you should run away from. Merely, what I try to do here is shed some light on a situation. Maybe you are a long-term shareholder wondering why, or maybe you are a timid wannabe shareholder that hasn’t yet made the leap. I am not here to steer you either way, but rather, to bring to light some thing you may not have known.
The Zacks Rank allows me to do so. I am, by nature, kinda lazy. Rather than take thousands of hours to analyze each and every stock on Earth, I take the easy route and allow Zacks to do the heavy lifting. Based on earnings estimate revisions from analysts on Wall Street, I make my decision.
Today’s Bear of the Day is Zacks Rank #5 (Strong Sell) Carlisle (CSL - Free Report) . Carlisle Companies Incorporated operates as a diversified manufacturer of engineered products in the United States, Europe, Asia, Canada, Mexico, the Middle East, Africa, and internationally.
Carlisle Companies Incorporated Price and Consensus
The reason for the unfavorable Zacks Rank stems from recent negative earnings estimate revisions. Over the last week, two analysts have cut their numbers while one has shaved next year too. The bearish moves have dropped the Zacks Consensus Estimates for the current year from $5.80 to $5.49 while next year’s number is off from $7.50 to $7.11.
Investors looking for other names within the Diversified Operations Industry should check out Zacks Rank #1 (Strong Buy) ITT Inc (ITT - Free Report) and Zacks Rank #2 (Buy) 3M (MMM - Free Report) .
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bear of the Day: Carlisle (CSL)
Disappointing stocks are everywhere. I’m sorry if I am the one who had to tell you but it’s true. With the market chopping around, worried about Pelosi vs Mnuchin, you know what I mean. We need a deal done now. Actually, it should have happened six months ago…but I digress.
This brings to mind something I like to call the Bear of the Day. Now, before you folks get upset with me for calling out what is inevitably your favorite stock, bear with me for a moment (see what I did there.)
The Bear of the Day to me, is not necessarily, a stock you should run away from. Merely, what I try to do here is shed some light on a situation. Maybe you are a long-term shareholder wondering why, or maybe you are a timid wannabe shareholder that hasn’t yet made the leap. I am not here to steer you either way, but rather, to bring to light some thing you may not have known.
The Zacks Rank allows me to do so. I am, by nature, kinda lazy. Rather than take thousands of hours to analyze each and every stock on Earth, I take the easy route and allow Zacks to do the heavy lifting. Based on earnings estimate revisions from analysts on Wall Street, I make my decision.
Today’s Bear of the Day is Zacks Rank #5 (Strong Sell) Carlisle (CSL - Free Report) . Carlisle Companies Incorporated operates as a diversified manufacturer of engineered products in the United States, Europe, Asia, Canada, Mexico, the Middle East, Africa, and internationally.
Carlisle Companies Incorporated Price and Consensus
Carlisle Companies Incorporated price-consensus-chart | Carlisle Companies Incorporated Quote
The reason for the unfavorable Zacks Rank stems from recent negative earnings estimate revisions. Over the last week, two analysts have cut their numbers while one has shaved next year too. The bearish moves have dropped the Zacks Consensus Estimates for the current year from $5.80 to $5.49 while next year’s number is off from $7.50 to $7.11.
Investors looking for other names within the Diversified Operations Industry should check out Zacks Rank #1 (Strong Buy) ITT Inc (ITT - Free Report) and Zacks Rank #2 (Buy) 3M (MMM - Free Report) .
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>